ASC30 vs IcoSema
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
ASC30
Developed by Ascletis Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2028 · NCT07743450 (registry estimate)
No aligned efficacy figure on record for this race.
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
Reported efficacy
Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)
Result source: NCT06269107
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ASC30 | IcoSema |
|---|---|---|
| HbA1c, change | —Trial running · NCT07743450 | -1.6% vs -0.9%vs Insulin IcodecNCT053528152 other results
|
| Body weight, change (kg) | —Trial running · NCT07743450 | -3.7 vs 2.0vs Insulin IcodecNCT053528151 other result
|
| HbA1c below 7% | —Trial running · NCT07743450 | —Not posted · NCT05013229 |
| Fasting plasma glucose, change | —Trial running · NCT07743450 | -1.9 vs -1.6vs Insulin IcodecNCT053528151 other result
|
| 3-point MACE (% with event) | —Trial running · NCT07743450 | —Not posted · NCT05013229 |
HbA1c, change
- ASC30
- —Trial running · NCT07743450
- IcoSema
- -1.6% vs -0.9%vs Insulin IcodecNCT05352815
2 other results
- -1.4% vs -0.9% NCT05259033
- -1.5% vs -1.4% NCT05013229
Body weight, change (kg)
- ASC30
- —Trial running · NCT07743450
- IcoSema
- -3.7 vs 2.0vs Insulin IcodecNCT05352815
1 other result
- 0.9 vs -3.8 NCT05259033
HbA1c below 7%
- ASC30
- —Trial running · NCT07743450
- IcoSema
- —Not posted · NCT05013229
Fasting plasma glucose, change
- ASC30
- —Trial running · NCT07743450
- IcoSema
- -1.9 vs -1.6vs Insulin IcodecNCT05352815
1 other result
- -2.7 vs -1.4 NCT05259033
3-point MACE (% with event)
- ASC30
- —Trial running · NCT07743450
- IcoSema
- —Not posted · NCT05013229
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ASC30: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ASC30: 0 of 4 rows · IcoSema: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | IcoSema |
|---|---|
| Dropout rate | 5.4% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result3.8% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | — NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result— NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Serious AEs | 9.2% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | nausea 23.8% diarrhoea 15.8% vomiting 10.6% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more resultcovid-19 15% nausea 11.7% diarrhoea 11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
IcoSema
show 2 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · IcoSema's landscape